Our findings revealed that CIS-induced protein damage was effectively mitigated by CHX treatment (Fig. 2g, h), which resulted in the inhibition of caspase 3 activation (Fig. 5a, b). The gene discussed is CASP3; the disease is in situ carcinoma.